Pediatric rheumatology

Long-term follow-up of children with chronic non-bacterial osteomyelitis—assessment of disease activity, risk factors, and outcome

Arthritis Res TherPublished Registry-based cohort study

Authors' conclusion

An improvement of physician global disease activity (PGDA), patient reported overall well-being and imaging-defined disease activity measures was documented, suggesting that inactivity of CNO disease can be reached.

Study context

Population
Children and adolescents with confirmed CNO registered in the National Pediatric Rheumatologic Database (NPRD) during their first year of disease, 2015–202181 analysed at 4 years
Participants
400 children
Outcome
Clinical and MRI lesions per patient, inclusion vs 4-year follow-up
Follow-up
Up to 4 years
Methodological detailsNational Pediatric Rheumatologic Database (NPRD), follow-up up to 4 years
  • National Pediatric Rheumatologic Database (NPRD)
  • Follow-up up to 4 years

Main finding

As reported in the abstract

up to 4 years

Mean clinical lesions at inclusion

2.0

Mean MRI lesions at inclusion

3.0

Mean clinical lesions at 4 years (p < 0.001)

0.5

Mean MRI lesions at 4 years (p < 0.001)

0.9

Observational data: associations, not effects.

Further findings

Severe disease course (physician global disease activity (PGDA) > = 4)

Patients with severe disease course
5-7%
Predictors: site of inflammation (pelvis, lower extremity, clavicle), increased ESR, multifocal disease at first documentation

PedCNO70 · 4YFU

Patients reaching PedCNO70
55%

Treatment

Increase of DMARDs over the years; bisphosphonates rather considered in the first years of disease

Original publication

Long-term follow-up of children with chronic non-bacterial osteomyelitis—assessment of disease activity, risk factors, and outcome. Arthritis Res Ther. Published 28 November 2023. doi:10.1186/s13075-023-03195-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.